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Abstract
Objective To determine the optimal method for quantifying and
monitoring overdiagnosis in cancer screening over time.
Design Systematic review of primary research studies of any design
that quantified overdiagnosis from screening for nine types of cancer.
We used explicit criteria to critically appraise individual studies and
assess strength of the body of evidence for each study design (double
blinded review), and assessed the potential for each study design to
accurately quantify and monitor overdiagnosis over time.
Data sources PubMed and Embase up to 28 February 2014; hand
searching of systematic reviews.
Eligibility criteria for selecting studies English language studies of
any design that quantified overdiagnosis for any of nine common cancers
(prostate, breast, lung, colorectal, melanoma, bladder, renal, thyroid,
and uterine); excluded case series, case reports, and reviews that only
reported results of other studies.
Results 52 studies met the inclusion criteria. We grouped studies into
four methodological categories: (1) follow-up of a well designed
randomized controlled trial (n=3), which has low risk of bias but may not
be generalizable and is not suitable for monitoring; (2) pathological or
imaging studies (n=8), drawing conclusions about overdiagnosis by
examining biological characteristics of cancers, a simple design limited
by the uncertain assumption that the measured characteristics are highly
correlated with disease progression; (3) modeling studies (n=21), which
can be done in a shorter time frame but require complex mathematical
equations simulating the natural course of screen detected cancer, the
fundamental unknown question; and (4) ecological and cohort studies
(n=20), which are suitable for monitoring over time but are limited by a
lack of agreed standards, by variable data quality, by inadequate
follow-up time, and by the potential for population level confounders.
Some ecological and cohort studies, however, have addressed these
potential weaknesses in reasonable ways.
ConclusionsWell conducted ecological and cohort studies in multiple
settings are themost appropriate approach for quantifying andmonitoring
overdiagnosis in cancer screening programs. To support this work, we
need internationally agreed standards for ecological and cohort studies
and a multinational team of unbiased researchers to perform ongoing
analysis.
Introduction
Overdiagnosis, the detection and diagnosis of a condition that
would not go on to cause symptoms or death in the patient’s
lifetime, is an inevitable harm of screening. Overdiagnosis in
cancer screening can result from non-progression of the tumor
or from competing mortality due to other patient conditions
(that is, other conditions that would lead to the patient’s death
before the cancer would have caused symptoms). The
consequences of overdiagnosis include unnecessary labeling of
people with a lifelong diagnosis as well as unneeded treatments
and surveillance that cause physical and psychosocial harm.1A
patient who is overdiagnosed cannot benefit from the diagnosis
or treatment but can only be harmed.2
Patients, healthcare providers, and policy makers need
information about the frequency of overdiagnosis as they weigh
the benefits and harms of screening. Several studies have found
that patients want to factor information about overdiagnosis
into their decisions about screening for breast or prostate
cancer.3-5 On a policy level, accurate measurement of the
frequency of overdiagnosis is essential for monitoring the effects
over time of both new screening technology (which could result
in either increased or decreased overdiagnosis), new treatment,
and interventions to reduce overdiagnosis.
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Because it is impossible to distinguish at the time of diagnosis
between an overdiagnosed cancer and one that will become
clinically meaningful, measurement of overdiagnosis is not
straightforward. Researchers have used various methods to
indirectly quantify overdiagnosis resulting from cancer
screening, but the magnitude of these estimates varies widely.
We conducted a systematic review to identify and evaluate the
methods that have been used for measuring overdiagnosis of
cancer. We also analyzed the advantages and disadvantages of
each method for providing valid and reliable estimates of the




We have the following key questions:
1: What research methods have been used to measure
overdiagnosis resulting from cancer screening tests?
2:What are the advantages and disadvantages of eachmethod
for:
Providing a valid and reliable estimate of the frequency of
overdiagnosis?
Monitoring overdiagnosis over time?
Eligibility criteria
We included studies that have quantified the frequency of
overdiagnosis resulting from cancer screening in an
asymptomatic adult population. We limited the scope of the
review to studies of overdiagnosis in the nine types of solid
tumors with the highest incidence in the United States in
2012—prostate, breast, lung, colorectal, melanoma, bladder,
renal, thyroid, and uterine cancers.6 Studies in English from any
setting and time frame were included. All study designs were
included except non-systematic reviews,, case reports, and case
series. Systematic reviews were excluded if they simply
summarized studies that had each quantified overdiagnosis (for
example, by combining data from several estimates of
overdiagnosis). We included systematic reviews that used data
from identified studies to independently compute a new estimate
of overdiagnosis.
We accepted any of three definitions of overdiagnosis, each
with excess incidence attributable to screening in the numerator:
(1) cancers diagnosed by screening; (2) all cancers diagnosed
by any method during the screening period; and (3) all cancers
diagnosed by any method over the patient’s lifetime (or long
term follow-up).
Study identification and selection
We conducted a systematic search of PubMed and Embase on
28 February 2014 with no limits placed on dates or study design
(see appendices for search strategy). To further find relevant
studies, we also hand searched reference lists of systematic and
narrative reviews identified during the initial search. Abstracts
and full texts were reviewed independently by two reviewers
for inclusion. Any disagreements about inclusion or exclusion
of these studies were resolved by consensus, and a third senior
reviewer was consulted to resolve any remaining disagreements.
Data extraction
One reviewer extracted relevant data into a standardized form.
These data were verified by a second reviewer, and discrepancies
were resolved by consensus.
Risk of bias assessment
We created standard criteria to evaluate risk of bias for each of
the four main types of studies found in this review: modeling
studies, pathological and imaging studies, ecological and cohort
studies, and follow-up of a randomized controlled trial. Two
reviewers independently rated the risk of bias for each study,
and we resolved discrepancies by consensus. We adapted the
criteria for ecological and cohort studies from quality criteria
used in a recent systematic review of observational studies of
breast cancer screening.7 Risk of bias criteria for randomized
controlled trial follow-up and pathological and imaging studies
were adapted from standard criteria used by the U S Preventive
Services Task Force (USPSTF).8 We developed a new set of
criteria for evaluating modeling studies for the purpose of this
review, outlined in table 1⇓.
Based on these criteria, we rated a study as having high,
moderate, or low risk of bias. Studies with high risk of bias had
a fatal flaw that made their results very uncertain; studies with
low risk of bias met all criteria, making their results more
certain. Studies that did not meet all criteria but had no fatal
flaw (thus making their results somewhat uncertain) were rated
as having moderate risk of bias. We give general deficiencies
of the studies in each study type category in the appropriate
section.
Strength of evidence assessment
We developed criteria to evaluate overall strength of evidence
for the body of literature for each study type based on criteria
used by the USPSTF8 and the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) working
group.9 Each individual study was evaluated for risk of bias,
directness (see below), external validity, and precision.
Ecological and cohort studies and randomized controlled trials
were also rated on the appropriateness of their analysis and time
frame. For these studies, analysis is a central consideration
because a study can be well designed and performed with
minimal bias but still provide an unreliable estimate of
overdiagnosis because of a faulty analysis. Two reviewers
independently determined ratings for each of these criteria, and
we resolved discrepancies by consensus. We adapted criteria
for evaluating external validity of individual studies from the
USPSTF procedure manual.8Although we initially assessed the
external validity of studies based on their relevance to a general
US adult population, we then reassessed external validity based
on relevance to a Western European population, finding no
change in our conclusions.
The GRADE working group defines directness as the extent to
which the evidence being assessed reflects a single direct link
between the interventions of interest and the ultimate outcome.9
In this review, we evaluated the extent to which the evidence
links the screening test directly to the health outcome of excess
cases of cancer attributable to screening without making
assumptions. A study with good directness requires minimal
assumptions to draw conclusions about the magnitude of
overdiagnosis and avoids extrapolating over gaps in the
evidence.
We combined the ratings for risk of bias, directness, analysis,
time frame, external validity, and precision with an evaluation
of the consistency of the results to determine the strength of
evidence for the overall body of evidence for each study design
and cancer type. Table 2⇓ outlines our definitions of these terms;
a complete list of criteria used to evaluate risk of bias and
strength of evidence by study design can be found in the online
supplemental tables 3 and 4.
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Based on the criteria above, we rated the strength of evidence
for each study type as being high (that is, met all criteria),
moderate (did not meet all criteria but had no fatal flaw), or low
(had at least one fatal flaw that made estimates highly uncertain).
We give general deficiencies of the literature for each study
type studies in the appropriate section, including examples of
what we regarded as fatal flaws.
Data synthesis and analysis
We performed qualitative data synthesis, organizing the results
by study design and cancer type. We did not attempt to perform
quantitative synthesis because of the heterogeneity of the study
designs, populations, and results. Using our critical appraisal
of individual studies and the body of evidence for each study
design, we identified strengths and weaknesses of each study
design used to measure overdiagnosis. We did not assess
publication bias.
Results
We reviewed 968 abstracts and 120 full texts, including 52
individual studies. When we identified multiple reports from
the same authors investigating the same population or model,
we included only the most recent study. The figure⇓ shows the
flow diagram of the study selection process.10 The included
studies fell into four methodological groups, which we
categorized as modeling studies (n=21), pathological and
imaging studies (n=8), ecological and cohort studies (n=20),
and follow-up of a randomized controlled trial (n=3).
Modeling studies
Characteristics of included studies: modeling
studies
We included 21 modeling studies in this review: 10 of prostate
cancer,11-20 seven of breast cancer,21-27 three of lung cancer,28-30
and one of colon cancer overdiagnosis.31 In general, these studies
model the way cancer would hypothetically occur without
screening, and then the way cancer occurs with screening,
comparing the two to determine the frequency of overdiagnosis.
These studies modeled a variety of screening situations and
schedules. Some studies modeled only the non-progressive
disease and not the competing mortality component of
overdiagnosis23 26 27; such studies almost certainly underestimate
its magnitude. Table 3⇓ summarizes the evidence from the
included modeling studies.
Risk of bias: modeling studies
Several concerns raised the risk of bias in modeling studies.
First, no modeling study discussed the potential biases in the
data sources used in their models. Only twomodeling studies13 28
provided a table of assumptions and data sources. No studies
were supported by systematically reviewed evidence; most
studies picked data inputs from a variety of sources without
justification, raising the risk of bias to achieve a desired output.
Second, several studies found that mean sojourn time was a key
uncertain variable for which sensitivity analyses should be
performed, yet only six studies specifically varied mean sojourn
time or its equivalent in univariate or probabilistic sensitivity
analyses.11 13 24 25 27 28All other studies either performed minimal
sensitivity analyses that did not directly address key uncertain
variables or did not perform sensitivity analyses at all, both of
which we considered fatal flaws with high risk of bias.
Third, no study validated their model using a dataset and
population different from the one to which the model was
calibrated. Several studies used a dataset to calibrate the model
and then “validated” the model by fitting it to the same original
dataset. Performing true external validation would lend more
credibility to the assumptions made in the model and would
make it more likely that the calibrated parameters are applicable
to other populations. Furthermore, all modeling studies adjusted
for mean sojourn time or lead time using model-derived
estimates of these values which are obtained with overdiagnosed
cancers included in the calculation, resulting in incorrectly
prolonged estimates of lead time which bias the overdiagnosis
results toward zero.32
Overall, 15 of 21 modeling studies had a high risk of bias
because they had the fatal flaw of not performing key sensitivity
analyses. The five studies that performed univariate sensitivity
analyses for mean sojourn time were rated as having moderate
risk of bias.11 24 25 27 28
Strength of evidence: modeling studies
We rated overall strength of evidence as low for breast, prostate,
lung, and colon cancer modeling studies. We rated directness
as poor for all modeling studies, as they used insufficiently
supported assumptions to draw conclusions about overdiagnosis,
especially progression of cancer in the absence of screening.
The frequency and rate of this progression is fundamental to
overdiagnosis; the estimates from such models are by nature
indirect. We rated the overall risk of bias for modeling studies
as high, external validity as good, and consistency as poor.
Precision could not be determined.
Pathological and imaging studies
Characteristics of included studies: pathological
and imaging studies
We found eight studies that drew conclusions about
overdiagnosis based on a pathological or imaging
characteristic.33-40 These studies examined only overdiagnosis
resulting from non-progressive disease and not competing
mortality; thus, they underestimated total overdiagnosis. Table
4⇓ summarizes the evidence from the included pathological and
imaging studies.
Risk of bias: pathological and imaging studies
Several problems increased risk of bias for these studies:
inability to obtain complete follow-up information on the
included patients,35 36 38 non-management of potential
confounders,33 35 39 40 use of inconsistent methods for determining
tumor characteristics,38 40 and invalid or unreliable ascertainment
of cause of death.35Overall, three lung cancer studies had a high
risk of bias,35 38 and three had a moderate risk of bias. Both
prostate cancers studies had a high risk of bias.
Strength of evidence: pathological and imaging
studies
We rated the strength of evidence as low for all prostate and
lung cancer pathological and imaging studies. With one
exception, directness was poor for all pathological and imaging
studies because the validity of the study estimates was
contingent on the unexamined assumption that the pathological
or imaging characteristics were directly and strongly correlated
with cancer relatedmorbidity andmortality.We rated the overall
risk of bias of pathological and imaging studies as moderate to
high, external validity as fair to good, and consistency as poor.
Precision could not be determined.
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Ecological and cohort studies
Characteristics of included studies: ecological
and cohort studies
We found 20 ecological and cohort studies that met our criteria,
18 of breast cancer41-58 and two of prostate cancer.59 60 The breast
cancer studies were typically European with screening programs
involving biennial mammography for women aged 50–69 years.
Table 5⇓ summarizes the evidence from the included ecological
and cohort studies.
Risk of bias: ecological and cohort studies
In general, ecological and cohort studies have a high risk of
selection bias and confounding due to the comparison of
non-randomized populations or cohorts. The included studies
used several variations of unscreened reference populations
with varying potential for bias. Most studies modeled the
prescreening incidence trend through the study period to
determine reference incidence, though this assumes that
incidence would have continued at the same rate without
non-linear changes. Several studies45 47 53 used contemporary
geographic areas without screening programs as the reference
population; this approach could introduce confounders that are
distributed differently between the two geographic areas. The
use of a historical control group is complicated by potential
confounders that may have changed in a substantial way between
time periods. Two studies used a combination of three control
groups, including a contemporary unscreened group and
historical groups in the regions with and without screening.49 51
These studies are better able to control for differences in
incidence growth between regions but could still be biased by
differential influence of confounders between regions. Some
studies took additional steps to reduce the probability of
selection bias and confounding, including adjusting for risk
factors on a population level41 48 50 and considering “extreme”
scenarios.41 Because of such additional steps, we were able to
rate 18 of 20 ecological and cohort studies as having moderate
risk of selection bias and confounding. We rated two studies as
having high risk of bias because they compared screening
attenders with non-attenders, groups with known differences in
general health and health behaviors.44 55We rated 17 of 20 breast
cancer studies as moderate risk of measurement bias because
they did not discuss the validity and reliability of their data
sources.
Overall, we rated 17 of 20 ecological and cohort studies as
having a moderate risk of bias. Three breast cancer studies,44 53 55
however, had a high risk of bias overall due to a high risk of
confounding. Both prostate cancer studies had a moderate risk
of bias overall.
Analysis: ecological and cohort studies
Several analysis issues related to measuring and calculating
overdiagnosis are unique to ecological and cohort studies.
Screening advances the time of diagnosis of preclinical cancers
by the lead time, such that incidence is predictably increased in
a screened population during the screening period. After the
screening period, in the absence of overdiagnosis, cancers that
would have presented clinically have already been detected by
screening, so cumulative incidence tends to increase more
gradually, and incidence rate declines. Because lead time varies
among cancers and individuals, and with different screening
strategies, there is no single lead time that correctly captures
this time period for a population.
Often, overdiagnosis is calculated by determining the number
of excess cases of cancer in a screened population (compared
with a non-screened population) during the screening period,
subtracting the deficit of cases in post-screening women
compared with an unscreened reference, thus estimating the
absolute difference in long term cumulative incidence
attributable to screening. Studies that obtain follow-up data for
a short period after screening ends may not sufficiently capture
the post-screening deficit of cases and thus can overestimate
overdiagnosis. Other studies instead perform a statistical
adjustment for lead time as an alternative to achieving longer
term follow-up. The validity of these statistical adjustments,
however, is not clear. For example, adjusting for a “mean” lead
time is likely biased because overdiagnosis depends not just on
“average” lead time but also on the distribution of individual
lead times, which is much more difficult to estimate and may
be less generalizable from population to population. Also, most
estimates of lead time are derived from models which include
overdiagnosed cancers in their calculation of lead time, leading
to underestimates of true overdiagnosis.32
We rated the adequacy of the time frame of included ecological
and cohort studies. Because the lead time magnitude and
distributions are largely unknown, we used these ratings as a
general guide to highlight where biased estimation might be
occurring. When studies performed a statistical adjustment for
lead time43 45 50 52 we did not rate their time frame. Two studies
with no follow-up post-screening received poor ratings.53 56We
rated as good a cohort study that achieved at least 10 years
follow-up post-screening on all women44 and a study41 performed
over a 30 year period during which screening had reached a
steady state.44 We rated the remaining ecological and cohort
studies as fair, as they achieved variable amounts of follow-up
time (4–14 years) post-screening. Studies that performed an
unjustified statistical adjustment for lead time introduced greater
uncertainty into the analysis and greater concern about bias; we
thus rated their analysis as poor.43 45 50 52
Six ecological and cohort studies calculated overdiagnosis as
the risk ratio of cumulative incidence of cancer in the screening
group compared with the reference group over the screening
period and a period of follow-up post-screening.51 54 55 59 60 These
studies defined overdiagnosis as the proportion of all cancers
(including ones diagnosed after the screening period) that would
never have caused clinical problems. The inclusion of cases
diagnosed after the screening period in the denominator dilutes
the estimate of overdiagnosis and makes the frequency of
overdiagnosis highly dependent on the length of follow-up time.
We rated the analysis of these studies as poor, because they all
provided underestimates of overdiagnosis according to our
definition. We rated as good studies that calculated
overdiagnosis as the absolute excess of cases in the screened
population divided by cases diagnosed in the screened
population during the screening period.41 44 46 47 57 58
Directness: ecological and cohort studies
We rated directness as good for 15 of the 20 ecological and
cohort studies because they directly quantified excess cumulative
incidence in a screened population. The exceptions were the
studies that performed an unjustified statistical adjustment for
lead time,43 45 50 52 which we rated as having poor directness
because these studies require additional assumptions about
cancer progression, and one study which excluded data from
the prevalence screening round.42
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Strength of evidence: ecological and cohort
studies
We rated the strength of evidence as low for the overall body
of ecological and cohort studies. However, five breast cancer
ecological studies stood out among the others for having a
moderate risk of bias, an unbiased analysis, and fair to good
time frames.41 46 47 57 58 The estimates of overdiagnosis from these
studies gave greater confidence of accuracy.We rated the overall
directness of ecological and cohort studies as good (n=15) or
poor (n=5), external validity as good, precision as fair,
consistency as poor, analysis as good (n=6) or poor (n=14), and
time frame as fair.
Follow-up of a randomized controlled trial
Characteristics of included studies: follow-up of
a randomized controlled trial
We included three long term follow-up studies of randomized
controlled trials: one of the Malmo randomized controlled trial
in Sweden,61 which randomized women aged 44 to 69 years to
several mammography rounds or no screening and followed
them for 15 years; the second of the National Lung Screening
Trial,62 which randomized high risk US patients aged 55–74
years and followed them for up to seven years; and the third of
the Canadian National Breast Screening trial,63 which
randomized Canadian women aged 40–59 and followed them
for an average of 22 years. Table 6⇓ summarizes the evidence
from the included follow-up studies of a randomized controlled
trial.
Risk of bias: follow-up of a randomized controlled
trial
All studies had a low risk of selection bias and confounding.
We rated the risk of measurement bias as moderate in theMalmo
and National Lung Screening Trial studies because the authors
did not describe the validity and reliability of their data sources,
particularly over the long term follow-up periods. In the National
Lung Screening Trial follow-up, measurement bias was also
moderate because lung cancer incidence assessment was not
masked. Overall risk of bias was low for all three studies.
Strength of evidence: follow-up of a randomized
controlled trial
We rated the time frame of the Malmo and Canadian studies as
good because they achieved complete 15 year follow-up of all
women in the study and 22 year follow-up on average,
respectively. We rated the National Lung Screening Trial time
frame as fair, only achieving seven years follow-up. The initial
analysis of the Malmo study received a poor rating for diluting
the overdiagnosis estimate, but the re-analysis performed by
Welch and colleagues was unbiased.64 The Welch re-analysis
used the denominator of cases diagnosed during the screening
period and a numerator of excess cases diagnosed in the
screening group, resulting in 18% overdiagnosis rather than
10%. Overall strength of evidence was moderate for both cancer
types, as only one or two studies represented each type. We
rated the overall directness for follow-up of randomized
controlled trials as good, external validity as good, precision as
fair, consistency was not applicable, analysis as good, and time
frame as fair to good. The overall rating was moderate.
Discussion
Principal findings of the review
This review identified four major research methods that have
been used to measure overdiagnosis from cancer screening:
modeling studies, pathological and imaging studies, ecological
and cohort studies, and follow-up of a randomized controlled
trial. Using the frameworks for evaluating risk of bias and
strength of evidence, we identified strengths and weaknesses
of each of these methods for providing valid and reliable
estimates of the frequency of overdiagnosis and the suitability
for monitoring overdiagnosis over time (table 7⇓).
For the purposes of estimation of overdiagnosis at a point in
time, follow-up of a randomized controlled trial is ideal for
minimizing biases and directly addressing the question of
interest. However, because these studies require significant time
and resources and often have limited external validity, they are
less useful for monitoring overdiagnosis over time.
Modeling studies require less time than randomized controlled
trials and, with the help of sometimes unexamined assumptions,
are able to project through areas of uncertainty. These
projections, however, do not change the fact of uncertainty.
Sensitivity analyses demonstrate that varying key uncertain
inputs such as the distribution of sojourn time substantially
changes overdiagnosis estimates.11Most of the included studies
made no efforts to mitigate these uncertainties with unbiased
selection of data sources, sensitivity analyses, or external
validation, and most had a high risk of bias. Because the
effectiveness of treatment and the sensitivity of screening tests
change over time (whichmay change the natural history of both
treated and untreated cancer), models would need constant
modification to provide valid monitoring of overdiagnosis over
time. Finally, models would need to continually adjust for
changes in competing mortality risks, which also change over
time.
Pathological and imaging studies tend to over-simplify
overdiagnosis, with an arbitrary cutoff of a defining
characteristic such as volume doubling time. Furthermore, both
modeling and pathological imaging studies are indirect because
they require assumptions about cancer progression.
Some ecological and cohort studies are limited by confounding
and problematic analyses, including uncertain statistical
adjustments. However, when well designed and interpreted in
combination with studies from other geographic areas and time
periods, these studies can provide credible estimates of
overdiagnosis. They are also suitable for monitoring of “real
world” overdiagnosis over time.
Similar to models that require an estimate of lead time, some
ecological and cohort studies have performed a statistical
adjustment for lead time in their analyses, which introduces
uncertainty. Lead time is not only uncertain, but actually
prospectively unknowable, as it varies among individuals and
by screening practice. It is possible to calculate an average lead
time from randomized trials, though these estimates are biased
because they include overdiagnosed cancers in the calculation
if a model is used. The heterogeneity of cancer and of
individuals among and between populations, as well as variation
and changes in the sensitivity of screening tests and treatment
effectiveness, makes estimating the lead time distribution a
highly uncertain endeavor.
Ongoing ecological and cohort studies within established
national or regional screening programs, however, with
appropriate collection of information about cancer incidence,
potential confounders, screening adherence, and treatments
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used, have the ability to compare cancer incidence in areas with
one type of screening program to incidence in areas with a
different type of screening program. When carefully analyzed
in an unbiased manner, such international ecological and cohort
studies have the potential to help us better understand the effects
of different screening programs on overdiagnosis, as well as
trends in overdiagnosis as screening programs and treatments
change over time. The potential credibility and usefulness of
ecological and cohort studies is greater than modeling studies
for these purposes.
Strengths and weaknesses of the review
The major strengths of this study are that it is a systematic
review, that it offers specific criteria for evaluating studies
measuring overdiagnosis, and that it looks broadly at studies of
overdiagnosis of different types of cancer. There are several
limitations of our review.We had to modify criteria for strength
of evidence to fit the different research designs; readers should
examine these criteria when interpreting our findings. We
combined certain studies when multiple studies were available
from the same authors or were using the same model and
population, and it is possible that we missed some of the
variability in the data available. We also limited the scope of
our review to include only the nine types of solid tumors with
the highest incidence in US adults, and no overdiagnosis
estimates were available for melanoma and bladder, renal,
thyroid, and uterine cancers.
Strengths andweaknesses in relation to other
studies
To our knowledge, there are no other systematic reviews that
have comprehensively identified all studies that measure
overdiagnosis. Several systematic and non-systematic reviews
have explored a subset of the overdiagnosis literature.
Biesheuvel and colleagues systematically reviewed studies of
breast cancer overdiagnosis with a focus on potential sources
of bias in the estimates.65We disagree that statistical adjustment
and exclusion of prevalence screening data, which they
recommend, are adequate to manage problems of lead time.
Furthermore, they advocate the “cumulative incidence method,”
in which overdiagnosis is calculated as a risk ratio of cumulative
incidences several years after screening has ended, which has
been a major source of confusion for other researchers who have
referenced this review. This analysis method is problematic
because it dilutes the overdiagnosis estimate and makes it
dependent on the length of follow-up time.65 Puliti and
colleagues reviewed European observational studies of breast
cancer overdiagnosis, making note of which studies adequately
adjusted for breast cancer risk and lead time.66We question their
assessment, as they favorably rated studies that statistically
adjusted for lead time as well as studies that included
post-screening follow-up years in the analysis.
Etzioni and colleagues non-systematically reviewed studies of
breast and prostate cancer overdiagnosis.67 They label ecological
and cohort studies that do not statistically adjust for lead time
as the “excess incidence approach” of overdiagnosis estimation
and argue that these studies may yield a biased estimate if the
early years of screening dissemination are included. They
advocate excluding the first few years of screening data to make
an overdiagnosis estimate less biased. We agree that if a study
includes only the first few years of screening dissemination
without any post-screening follow-up that this can lead to
overestimation, but most existing studies appropriately measure
incidence during a screening and post-screening follow-up
period and are thus able to measure overdiagnosis without this
bias.67
Etzioni and colleagues also discuss modeling studies for
measuring overdiagnosis which they refer to as the “lead time
approach.” They claim that the main limitation of modeling
studies is their lack of transparency, and that prior publication
of the model in peer reviewed statistics literature is a positive
indicator of the model’s validity.67 Rather than lack of
transparency, we found that the inherent lack of directness of
modeling studies and the potential for key uncertain inputs to
greatly alter overdiagnosis estimates are the primary limitations
of modeling studies. Prior model publication in the statistics
literature is not a sufficient indicator of a model’s validity, and
authors of modeling studies should be encouraged to take steps
to increase the validity of their study by using systematically
reviewed data inputs and performing sensitivity analyses and
external validation.
Finally, Etzioni and colleagues point out a dichotomy in the
selected studies they chose to present, where modeling studies
tended to have much lower estimates of overdiagnosis than
ecological studies, particularly among breast cancer studies.67
However, we found several breast cancer modeling studies22 25 27
with much higher overdiagnosis estimates than the ones they
presented, as well as ecological studies51 54 55 with lower
estimates than those presented. Their suggestion that all
ecological and cohort studies overestimate overdiagnosis is
unfounded.
Meaning of the review: implications for future
practice and research
We suggest that the public health policy community begin a
coordinated effort to develop an international ecological and
cohort data monitoring system for cancer screening programs,
including monitoring overdiagnosis. We found that well
conducted ecological and cohort studies performed in a variety
of settings can give accurate estimates and enable us to compare
overdiagnosis among different screening programs and to
monitor overdiagnosis over time. Some of this research is
ongoing, especially in European countries with breast cancer
screening programs, but it is not being performed in a uniform
way. We suggest the formation of a group of unbiased
international experts to set standards for ecological and
population cohort studies, for countries to adopt these standards
in their registries, and then for unbiased methodological experts
to conduct ongoing studies to monitor screening and
overdiagnosis over time.
These standards should include an adequate time frame that
achieves sufficient follow-up post-screening, such that all
participants in the post-screening age groups have previously
been offered screening. Researchers should determine standard
population level confounders, unique to each cancer type, that
should be monitored and adjusted for. In addition to considering
cancer risk factors as potential confounders, information systems
should monitor screening strategies, screening adherence,
treatments used, and patient outcomes (such as complications,
morbidity, and mortality). Finally, standards for analysis should
include calculation of overdiagnosis as an absolute excess of
cases attributable to screening divided by a denominator of cases
diagnosed during the screening period.
Setting up these registries and information systems may be
challenging for some countries, but others have already made
great strides in this direction. There will certainly need to be an
initial investment of resources, but, once established, the
potential benefits from these information systems are large.
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These systems could examine the effects of variations in
screening programs on the magnitude of harms and costs of
overdiagnosis, as well as determining when a screening program
is no longer effective because of improved treatment. Beyond
overdiagnosis, these studies may also provide real world
information about the benefits and harms of newer screening
technologies, helping to make policy decisions about which
programs to implement more widely. Such information systems
could also provide platforms on which randomized controlled
trials of new screening programs could be efficiently tested.
Conclusions
Researchers have measured overdiagnosis using four main
methods. Follow-up of a randomized trial is ideal for internal
validity but requires extended time, may lack external validity,
and is not useful for monitoring. Modeling studies and
pathological and imaging studies are simpler to perform but
introduce uncertainty by lack of directness and requiring
assumptions about cancer progression. Ecological and cohort
studies can be limited by confounding and require careful
analysis, but when performed well they can provide a more
valid and reliable estimate of overdiagnosis. They are also well
designed to monitor and compare screening programs over time.
A group of unbiased researchers should set standards for these
studies andmonitor overdiagnosis and other outcomes of cancer
screening programs in multiple countries. Monitoring screening
programs is important not only in attempts to reduce
overdiagnosis, but for maximizing the benefits of cancer
screening while minimizing the harms and costs.
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Tables
Table 1| Criteria for evaluating risk of bias by study type among studies that quantified overdiagnosis resulting from cancer screening
Risk of bias criteriaStudy type
Extent to which assumptions are transparent and clearly stated
Extent to which assumptions are backed with evidence
Probability for bias in data used in model
Sensitivity analyses performed for uncertain variables
External validation of model
Modeling studies
Probability of selection bias and confounding
Probability of measurement bias
Pathological and imaging studies
Ecological and cohort studies
Follow-up of a randomized controlled trial
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Table 2| Definitions of criteria for evaluating strength of evidence among studies quantifying overdiagnosis from cancer screening
DefinitionCriterion
See table 1Risk of bias (high/moderate/low)
Extent to which the evidence links screening directly to differences in long term cumulative incidence between
populations without making assumptions
Directness (good/fair/poor)
Extent to which the analysis appropriately quantifies overdiagnosis, without inclusion of age groups or time frames
that lack the potential to be overdiagnosed, and without statistically adjusting for lead time
Analysis (good/fair/poor)
Extent to which the time frame is sufficient to account for the effects of lead timeTime frame (good/fair/poor)
Extent to which study population is similar to US general population or Western European populations in factors that
are associated with cancer incidence, screening situation (such as expertise of screening radiographers, quality of
screening facilities, threshold for defining a result as abnormal), medical care, and risks for competing mortality
External validity (good/fair/poor)
Confidence interval of difference in cumulative incidence attributable to screening between populations over an
appropriate time frame should be provided. Width of confidence interval should be narrow, not wider than about 20%.
Precision (good/fair/poor/cannot determine)
Extent to which the overdiagnosis measurements from the included studies have a similar magnitudeConsistency (good/fair/poor)
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SEER=Surveillance, Epidemiology, and End Results database; SSA=Social Security Administration; MST=mean sojourn time; MISCAN=Microsimulation Screening
Analysis model; FHCRC=Fred Hutchinson Cancer Research Center; IARC=International Registry for Research on Cancer; DCIS=ductal carcinoma in situ;
NLST=National Lung Screening Trial; UKLS= UK Lung Screening pilot trial; CARET=Carotene and Retinol Efficacy Trial; CT=computed tomography; CXR=chest
x ray; FOBT=Fecal Occult Blood Test.
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UK: 57% (53 to
61%)
CA: 44% (25 to 65)
NSW: 53% (44 to
63)
Sweden: 46% (40 to
52)





















































































































Funen: 1% (−7 to
10)
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4.6% (2 to 7%) after
adjustment for lead
time



















































































Up to 4 (N) and


















from Zahl 2004, with
non-significant drop


































Age 60: 25% (19 to
32%)







4 years FU post-screeningNoneContemporary
counties without
screening





HRT=hormone replacement therapy; FU=follow up; CA=Canada; NSW=New South Wales, Australia.
*Unclear if Duffy 2010 estimates of overdiagnosis include ductal carcinoma in situ.
†Does not include ductal carcinoma in situ.
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Table 6| Summary of evidence from 3 randomized controlled trial follow-up studies quantifying overdiagnosis from cancer screening
Risk of bias; time
frame; analysis
Magnitude of






Low; fair; good18.5% (5.4 to 30.6%)(Excess cases)/(screen
detected cases)




Low; good; good22%(Excess cases)/(screen
detected cases)
22 years (average)Canada; 40–59 year olds;
1980–2005
Miller 201463
Low; good; poor†10% (1 to 18%)*(Excess cases)/(control cases)
during trial and 15 years
follow-up
15 yearsSweden; 55–69 year olds;
1976–86
Zackrisson 200661
*Welch et al re-analysis64 found overdiagnosis of 15% as percentage of cases diagnosed during screening period; overdiagnosis of 24% as percentage of screen
detected cases.
†Welch et al re-analysis rated as good.
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Table 7| Strengths and weaknesses of the main research methods used to quantify overdiagnosis from cancer screening
WeaknessesStrengthsResearch method
Substantial time and resource requirements
Limited external validity
Not useful for monitoring over time
Best able to minimize biases
Directly answers question of interest
Follow-up of randomized
controlled trials
Validity of results depends on assumptions (poor directness)
Needs constant updating of model constraints to reflect changing nature of cancer
diagnosis and treatment
Small changes in assumptions and model can lead to large changes in estimates
Difficult to critically appraise (a “black box”)
Need long follow-up to determine overdiagnosis, yet uncertainty increases with
time in models
May give false sense of precision, insufficient attention to uncertainty
Can project through areas of uncertainty
Not limited by time constraints
Can evaluate multiple screening situations
Can be used for monitoring over time
Modeling
Validity of results depends on assumptions (poor directness)
Not able to account for competing mortality
Need to be sure all diagnosed cases are ascertained, and that data are collected
in same way
Can be used for monitoring over time
One of the simplest approaches
Pathological and imaging
studies
Potential for confounding factors related to diagnosis, treatment, and health status
between populations
Moderate time requirements
Needs investment in population registries, full and accurate ascertainment of all
cases, and full and accurate collection of potential confounders
Directly answers question of interest
Provides “real world” view of overdiagnosis
Able to compare results from different settings
Can be used for monitoring over time
Ecological and cohort studies
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Figure
Flow diagram of study selection process
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